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ABSTRACT
Hospital-acquired bacterial infections pose a formidable challenge for healthcare providers, as patients
often need to be treated empirically, at least initially, although delay of appropriate initial antimicrobial
therapy is known to increase morbidity signiﬁcantly and to increase mortality among affected patients.
This elevated risk is compounded by the presence of antibiotic-resistant bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum
b-lactamase-producing Enterobacteriaceae, Escherichia coli and Klebsiella pneumoniae. Prompt initiation of
treatment with an appropriate antimicrobial agent that is active against both Gram-positive and Gram-
negative organisms is prudent for patients with nosocomial infections. As the continued usefulness of
vancomycin comes into question, the number of alternative agents that provide efﬁcacy equal to that of
vancomycin remains limited. The development of novel and effective alternative agents, such as
tigecycline, is therefore important.
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INTRODUCTION
Nosocomial bacterial infections have emerged as
a particular healthcare concern worldwide [1,2].
For example, in the USA, two million patients
acquire such infections annually [3], and c. 10% of
hospitalised patients develop an infection after
hospital admission in the UK [4]. Staphylococcus
aureus and coagulase-negative staphylococci are
important, common causes of nosocomial infec-
tions such as bacteraemia, pneumonia, and skin
and soft tissue infections [5]. Indeed, widespread
use of broad-spectrum antimicrobial agents exer-
ted such heavy selective pressure during the
1990s that staphylococci emerged as some of the
most prevalent pathogens causing nosocomial
infection [6]. Between 1995 and 1998, coagulase-
negative staphylococci, S. aureus and Enterococcus
spp. were the leading causes of nosocomial
bacteraemia across the USA, accounting for 60%
of such cases [7]. However, the Enterobacteriaceae
are also major causes of hospital-acquired infec-
tions. Members of the Enterobacteriaceae are
found in many locations, including the intestine,
and have been linked to almost every type of
infection, including abscesses, pneumonia, septi-
caemia and complicated urinary tract infections.
Table 1 summarises the most frequent pathogens
causing blood and wound infections [8].
Bacterial resistance is an increasing threat to the
successful treatment of both community-acquired
and nosocomial infections. As bacterial resistance
continues to evolve, some pathogens that were
once considered routine to treat have developed,
or are now developing, resistance to almost every
antibacterial agent currently available. Further-
more, because infections caused by resistant
pathogens are associated with higher morbidity
and mortality than those caused by susceptible
pathogens, the global impact of increasing resist-
ance is a major concern [9,10]. In the USA alone,
antibacterial resistance has been estimated to add
at least US $100 million (Euro 80 million) to
annual healthcare costs [11].
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Efforts to combat increasing bacterial resistance
have included the establishment of a number of
surveillance programmes to monitor the emer-
gence of antimicrobial-resistant pathogens. These
surveys have shown a consistent increase in
methicillin-resistant S. aureus (MRSA), with epi-
demic strains having appeared in the UK and
elsewhere. Data from the European Antimicrobial
Resistance Surveillance System (EARSS) have
documented the full range of MRSA incidence,
from 0% in Scandinavia to > 40% in some
southern European countries [12], and similar
resistance problems have been noted among
Enterococcus spp. isolated in the USA and Canada
by the SENTRY surveillance programme. In 1997
and 1998, c. 25% of bloodstream enterococcal
isolates in the USA and Canada were found to be
resistant to amoxycillin, with even higher rates of
ﬂuoroquinolone and gentamicin–streptomycin
resistance [13–15]. The problem of resistance
among Gram-negative pathogens is best exempli-
ﬁed by the production of b-lactamases by the
Enterobacteriaceae, which seem to be able to
evolve individualised b-lactamases in response
to environmental pressures, such as exposure to
third-generation cephalosporins. These evolved
b-lactamases are known as extended-spectrum
b-lactamases (ESBLs) [16].
Thus, the prevalence of both Gram-positive and
Gram-negative organisms as nosocomial patho-
gens, combined with changing antimicrobial sus-
ceptibility patterns, has produced signiﬁcant
therapeutic challenges. Given these concerns, the
management of serious infections caused by these
pathogens must focus on both treating the
patients and ensuring that these organisms do
not spread throughout the hospital. Infection
control is essential to limit the transfer of organ-
isms among medical and nursing staff and
patients. In addition, minimising the selective
pressure by using the most appropriate antibiotic
will help to contain these highly adaptive nosoco-
mial pathogens. This review examines the impact
of global resistance among bacterial species com-
monly implicated in nosocomial infections, con-
siders the burden of these infections on both the
patient and the healthcare system, and assesses
the therapeutic options, both those available
currently and those in development, for the
treatment of complicated infections.
THE GROWING PROBLEM OF
RESISTANCE
Given the frequency with which S. aureus, entero-
cocci and Enterobacteriaceae are responsible for
serious bacterial infections in hospitalised
patients, it is no surprise that the emergence of
resistance to existing antibiotics among these
organisms has become a serious medical issue.
Since the ﬁrst report of MRSA in the late 1960s,
concern over its growing prevalence has esca-
lated. The National Nosocomial Infection Surveil-
lance System (NNIS) reported a signiﬁcant
increase (from 2.4% to 29%) in the prevalence
of nosocomial MRSA infections in the USA
between 1975 and 1991 [3]. In European countries
(Austria, Belgium, France, Germany, Italy, The
Netherlands, Spain and Switzerland), the overall
percentage of MRSA isolates was 12.8% in 1990
and 1991, based on a study that examined 100
consecutive S. aureus isolates from 43 microbio-
logy laboratories [17]. A study in 1999 of blood-
stream isolates from over 15 000 patients infected
with S. aureus who were treated at SENTRY
participating hospitals in 13 European countries
(including the aforementioned countries, plus
England, Greece, Poland, Portugal and Turkey)
found that the overall percentage of MRSA
isolates in Europe had increased to 26.3% [5]. In
England and Wales, the number of S. aureus
bloodstream infections caused by MRSA rose
from <2% in 1989 to 34% in 1998 [18]. This
increase was caused largely by two epidemic
strains of MRSA (EMRSA-15 and EMRSA-16) that
have spread dramatically and are the two most
prevalent types of MRSA in the UK [19]. Indeed,
these EMRSA strains account for c. 60–70% of
MRSA isolates in England and Wales [20]. The
EARSS recently reported MRSA data from 18
countries for the ﬁrst 6 months of 2001. The
northern European countries (e.g., Sweden and
Denmark) appeared to have the lowest rate of
MRSA (< 3%), while the UK (46.1%), Israel
(44.1%) and Greece (38.6%) had the highest rates.
Table 1. Summary of the most frequent nosocomial path-
ogens causing blood and wound infections [8]
Blood (%) Wound (%)
Coagulase-negative staphylococci 33.5 12.6
Staphylococcus aureus 13.4 11.2
Enterococci 12.8 15.6
Candida albicans 5.8 Negligible
Enterobacter spp. 5.2 9.5
Pseudomonas aeruginosa Negligible 10.3
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The EARSS is committed to continue this tracking
and to monitor the development of multiple
antimicrobial resistance in MRSA isolates [12].
The most recent data from the SENTRY pro-
gramme have revealed that MRSA isolates have
varying resistance to other antimicrobial agents
(e.g., gentamicin, rifampicin, chloramphenicol,
ciproﬂoxacin, clindamycin, erythromycin and
trimethoprim–sulphamethoxazole) [5]. This
3-year surveillance study did not ﬁnd a high rate
of glycopeptide resistance among MRSA isolates
(< 1% of isolates had vancomycin MICs
‡ 4 mg ⁄L), but showed that rates of MRSA varied
by country and region. Prevalence data on MRSA
from Latin America between 1997 and 1999
demonstrated that Mexico appears to have the
lowest rate of MRSA (11.4%) compared with
other Latin American countries. Similarly, pre-
valence data on MRSA from the western Paciﬁc
regions between 1998 and 1999 showed highly
diverse rates, with Hong Kong and Japan report-
ing the highest rates (73.8% and 71.6%, respec-
tively) and much lower rates being reported in
Australia (23.6%). However, given that only
nations with SENTRY centres reporting ‡ 50
isolates were included in the study, it is possible
that these rates may not represent the overall
national rates of resistance.
As mentioned above, resistance among entero-
cocci to commonly used therapeutic agents, such
as amoxycillin and the ﬂuoroquinolones, poses a
serious threat to patients. However, the most
serious threat comes in the form of vancomycin-
resistant enterococci (VRE), which are considered
by many clinicians to be the ﬁrst organisms in the
antibiotic era for which no marketed antibiotic
has predictable therapeutic efﬁcacy. Data from
the NNIS have shown that the percentage of
enterococci resistant to vancomycin in acute-care
hospitals increased from 0.3% in 1989 to 7.9% in
1993 [21]. More recent data document rates as
high as 10.9% for acute-care hospitals and 13%
for intensive care units [22]. These organisms now
represent the fourth leading cause of nosocomial
infections in the USA [23]. Risk-factors for VRE
have been identiﬁed, including previous use of
cephalosporins and antimicrobial agents with
signiﬁcant anaerobic activity, renal insufﬁciency,
corticosteroid therapy, neutropenia, and cancer
[24,25]. In addition, treatment with vancomycin
and increasing severity of illness are recognised
as independent risk-factors for the development
of infection with VRE [26]. Given the dramatic
increase in infection with VRE, guidelines have
been published in an effort to thwart the spread of
these organisms [27].
Assessment of the evolving plague of ESBL-
producing bacteria is perhaps not best accom-
plished by large surveillance studies. Although
national averages of the frequency of ceftazidime
resistance among Escherichia coli and Klebsiella
pneumoniae remain relatively low in the USA,
these national averages may be misleading
because many ESBL-producing strains appear
susceptible to ceftazidime in routine susceptibility
tests. In addition, in countries that use cefotaxime
preferentially, the use of ceftazidime in suscepti-
bility tests can limit detection of ESBL-producing
strains that have evolved primarily to hydrolyse
cefotaxime. The prevalence of ceftazidime resist-
ance remains at £ 2% in the large surveys from
the USA, Canada, Europe and Japan [13–15].
However, it is well-established that production of
an ESBL does not always drive the MIC for
ceftazidime, or other third-generation cephalo-
sporins, into the intermediate or resistance range
speciﬁed by current NCCLS breakpoints [28].
Accordingly, special steps must be taken to
identify ESBL-producing isolates.
In contrast to the low levels of ceftazidime
resistance found in surveys from North America
and Europe, 5% of E. coli isolates from Latin
America were resistant to ceftazidime in 1997,
while studies in Venezuela and Colombia repor-
ted a frequency of 17–21% for ceftazidime resist-
ance [29,30]. In Thailand, Taiwan and The
Philippines, 7–11% of E. coli isolates were resist-
ant to ceftazidime, with even more isolates (13–
17%) screening positive for ESBL production
according to NCCLS criteria [31–33]. The situation
is similar for ESBL-producing K. pneumoniae, in
that Latin America and Asia reported much
higher rates of resistance than those observed in
North America. For example, in Thailand and The
Philippines, 27–43% of K. pneumoniae isolates
were resistant to ceftazidime in 1998 [31,32].
Clearly, antibiotic resistance impacts on every
continent to varying degrees, and will inevitably
continue to be a problem until there is a better
understanding of the mechanisms by which
resistance evolves and spreads. Armed with this
information, physicians can make informed
decisions with respect to antibiotic prescribing
and use. Antibiotic resistance is an inevitable
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consequence of inappropriate antibiotic use. The
availability of novel agents with good activity
against both susceptible and resistant Gram-
positive and Gram-negative pathogens is essen-
tial if we are to slow or reverse the current
trend.
BURDEN OF DISEASE: MORTALITY
AND COST OF SERIOUS INFECTIONS
The increased prevalence of MRSA, VRE and
ESBL-producing pathogens has placed a huge
responsibility on physicians to select appropriate
antimicrobial therapy promptly. Infection with
MRSA has been linked to prolonged hospitalisa-
tion and increased morbidity, and has been linked
tentatively to increased mortality [34–36]. It
should, however, be noted that these associations
with MRSA are often confounded by a higher rate
of co-morbidities among patients with MRSA
infections.
Infections caused by resistant organisms often
result in increased medical expenditure [37]. The
economic impact of MRSA infection was evalu-
ated using a model that examined the incidence
and direct medical costs of S. aureus infections in
hospitalised patients in New York City during
1995, together with the number of deaths [34].
Data were obtained from hospital discharge
records collected by the New York State Depart-
ment of Health and from standard sources for the
cost of healthcare. Direct medical costs were
deﬁned as hospital costs attributable to S. aureus
infection, professional fees incurred during hos-
pitalisation, and other infection-related medical
services provided after discharge, such as treat-
ment of complications or home-based intravenous
antimicrobial therapy. This model assumed that
29% of hospital-acquired S. aureus infections were
caused by MRSA, and that 10% of community-
acquired S. aureus infections were caused by
MRSA. The attributable cost of treating a patient
with MRSA infection was calculated to be US
$2500 (Euro 2000) higher than that for a patient
with methicillin-sensitive S. aureus infection. The
higher costs for the MRSA patients were associ-
ated with a longer hospital stay, the cost of patient
isolation procedures, and the cost of vancomycin
therapy. Most notable, however, was the 2.5-fold
higher mortality rate for patients with MRSA
infection as compared to those with methicillin-
susceptible S. aureus (21% vs. 8%, respectively).
To assess the effect of antimicrobial resistance
on length of hospital stay, a case-control study
compared infections caused by four nosocomial
pathogens (MRSA, ESBL-producing K. pneumo-
niae, and carbapenem-resistant Acinetobacter
baumannii or Pseudomonas aeruginosa) [35]. In total,
162 patients with infections caused by S. aureus
were identiﬁed, of whom 88 were infected with
methicillin-resistant isolates. Fourteen cases
with infections caused by MRSA were matched
with controls who were infected with methicillin-
susceptible S. aureus. In total, 106 patients with
infections caused by K. pneumoniae were identi-
ﬁed; 44 (42%) of these isolates produced ESBLs.
Nine case-control pairs were identiﬁed. Of 77
patients with A. baumannii infections, 44 (57%)
were infected with carbapenem-resistant isolates,
and of 116 adult patients with P. aeruginosa
infections, 29 (25%) were infected with carb-
apenem-resistant isolates. Ten case-control pairs
were identiﬁed for each of the latter two infec-
tions. Signiﬁcantly increased post-infection hos-
pital stays were associated with infections caused
by all four of these resistant organisms. Indeed,
hospital stays prolonged by c. 20 days were
reported for patients infected with resistant
Gram-negative isolates, compared with patients
infected with susceptible organisms. Overall
mortality was similar for cases and controls in
all four groups.
EFFECTIVE STRATEGIES FOR THE
MANAGEMENT OF SERIOUS
BACTERIAL INFECTIONS
To limit the spread of infections, including those
caused by MRSA, VRE and ESBL-producing
organisms, the initiation of appropriate infection
control measures is essential [38]. Infection con-
trol measures include: (1) screening protocols for
patients at high risk (e.g., previous antibiotic use,
previous hospitalisation); (2) isolation ⁄precau-
tionary techniques (e.g., private room, hand
washing, gloves ⁄ gowns ⁄masks) for patients
shown to be culture-positive for high-risk patho-
gens; (3) decontamination methods (e.g., a chlor-
hexidine bath is recommended for patients with
MRSA nasal carriage); and (4) appropriate micro-
biology screening procedures (e.g., periodic
vancomycin sensitivity testing) [39].
In addition to these infection control measures,
it has also been demonstrated that effective
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management of serious nosocomial infections
requires appropriate initial therapy. Studies by
Kollef and co-workers and Dupont et al. [40–43]
have shown an important correlation between
early and appropriate antibiotic treatment for
ventilator-associated pneumonia and the morbid-
ity and mortality associated with this condition.
These authors have shown that initiating the
correct treatment from the outset can have an
important impact on clinical outcomes in the
intensive care unit.
The studies of Kollef and co-workers [40–42]
have shown statistically signiﬁcant higher mor-
tality rates in patients receiving inappropriate
initial antibiotic treatment. Delay of appropriate
antimicrobial therapy is associated with an
increased risk of morbidity and mortality in
critically-ill patients with pneumonia. The eleva-
ted risk is often associated with the presence of
antibiotic-resistant bacteria, including MRSA,
and has also been correlated with prior antibiotic
therapy.
Dupont et al. [43] evaluated the impact of
antibiotic therapy on the outcome of ventilator-
associated pneumonia in a Paris hospital. In this
retrospective study, patients were given initial
antibiotic therapy following bronchial sampling,
guided by direct microbiological sampling (tele-
scopic plugged catheter or bronchoalveolar
lavage) where possible. Initial therapy was con-
sidered to be appropriate when all the signiﬁcant
organisms were susceptible to at least one of
the antibiotics prescribed to the patient. When
susceptibility-testing results became available
(after 48–72 h), the antibiotic therapy was adapted
if necessary. It was found that initial antibiotic
therapy was appropriate in only 50% of the
patients. When initial antibiotic therapy was
appropriate, it was associated with a shorter stay
in the intensive care unit. There was also a trend
towards lower hospital mortality in these patients
than in those given inappropriate treatment. The
period of mechanical ventilation was shorter for
appropriately treated patients than for survivors
who received inappropriate initial antibiotic ther-
apy. The pathogens associated most often with
inappropriate treatment were oxacillin-resistant
S. aureus, MRSA and P. aeruginosa. Thus, a correct
initial diagnosis and choice of antibiotic is essen-
tial for patients with nosocomial pneumonia, and





In order to optimise antimicrobial therapy, the
clinician must consider patient-speciﬁc factors,
such as age, renal function and site of infection, as
well as factors speciﬁc to an antimicrobial agent,
such as activity against organisms in a given
clinical situation, safety and tolerability proﬁle,
potential for bacterial resistance development, the
local resistance epidemiology and cost-effective-
ness [44,45]. In the last decade, it has become
apparent that the intrinsic pharmacokinetic and
pharmacodynamic properties of drugs are also
key determinants in the response to therapy [46].
Pharmacokinetic factors, such as the presence of
a long half-life, can allow more convenient dosing,
which may, in turn, ensure a patient’s adherence
to his or her medication regimen. In addition, an
antibiotic requires good penetration into the tis-
sues harbouring the pathogens to achieve drug
levels that meet or exceed the MIC for those
pathogens. Once the antibiotic reaches the target
site, the process of remaining at the bacterial
binding site at a sufﬁcient concentration and for a
sufﬁcient period of time is based on pharmaco-
dynamic principles. For antibiotics, the area under
the time serum concentration curve (AUC) in
relation to the MIC for the bacteria (AUC ⁄MIC) is
a predictor of success [47,48]. Within the usual
dosing ranges, increasing the concentration of
drug can result in faster bacterial killing and
inhibition of resistance development. Such con-
centration-dependent killing is associated with
aminoglycosides, ﬂuoroquinolones and tetra-
cyclines, including the newly developed glycyl-
cyclines [47]. The macrolide and b-lactam classes
of antibiotics employ concentration-independent,
or time-dependent, killing, where eradication
depends more on the time that the drug remains
above the MIC (Table 2) [47].
Despite the fact that optimisation of therapy
takes into account many different antimicrobial
agent-speciﬁc factors, there is still much emphasis
on an agent’s in-vitro microbiological activity and
on the classic designation of an agent as bacterio-
static or bactericidal [49]. Antimicrobial agents
exert their respective actions through a variety of
mechanisms that have been linked to bacterio-
static or bactericidal activity. In general, bacterio-
static agents are deﬁned as those that interfere
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with protein synthesis, while bactericidal agents
are those that inhibit cell wall synthesis. However,
some agents that affect protein synthesis can also
be bactericidal [49].
Historically, the designation of an agent as
bacteriostatic or bactericidal on the basis of
in-vitro testing has not always correlated with
its in-vivo activity. For example, chloramphenicol
is a bacteriostatic agent in vitro, but is bactericidal
against many organisms [49]. Similarly, the com-
bination of the two bacteriostatic agents trimeth-
oprim and sulphamethoxazole can eradicate some
pathogens [46]. Penicillin and vancomycin are
both considered bactericidal agents, except
against enterococci [49]. Clearly, many factors
contribute to the effectiveness of an antimicrobial
agent, all of which make questionable the rele-
vance of the in-vitro designation of an agent as
bactericidal or bacteriostatic. Pankey and Sabath
[50] have argued that the role played by the host
immune response in ﬁghting infection means that
bactericidal agents are not necessarily superior to
bacteriostatic agents, and that the clinical efﬁcacy,
as determined from clinical use, is more import-
ant than an in-vitro designation of bactericidal or
bacteriostatic.
Thus, in choosing an antibiotic, a physician
must ﬁrst consider its clinical efﬁcacy, i.e., does
this agent have a history of curing patients with
this infection? Next, toxicity should be consid-
ered, since any toxic agent should be used with
caution or not at all. Finally, recognising that
antibiotic resistance is an important issue in the
practice of medicine today, a drug with a high
AUC ⁄MIC ratio will have the best chance of
killing the bacteria, and therefore the smallest
chance of selecting or promoting resistance.
THERAPEUTIC OPTIONS
To avoid potentially life-threatening delays in
treatment, physicians typically treat patients with
suspected nosocomial infections empirically, i.e.,
before the results of cultures and resistance
assessments are available. Yet, as discussed
above, ineffective initial empirical treatment is
associated with increased risks of morbidity and
mortality. The widespread use of agents that may
be the last-resort weapons against multiresistant
bacteria tends, in turn, to foster the emergence of
organisms with resistance to those agents.
Evidence has now accumulated to suggest that
resistance to vancomycin among MRSA strains is
on the rise [51]. Because strains with reduced
susceptibility to vancomycin are associated with
therapeutic failure, new options have been sought
[19]. One approach has involved the use of
combination therapy, e.g., vancomycin plus rif-
ampicin, although acquired resistance to vanco-
mycin has been observed with the use of this
combination.
The development of vancomycin resistance has
been described in a retrospective review by
Burnie et al. [19] of 42 cases of septicaemia caused
by EMRSA-15, in which rates of mortality were
examined, based on treatment and susceptibility
patterns. All 42 blood isolates were susceptible to
vancomycin pre-therapy according to conven-
tional testing, and among the 25 patients treated
with vancomycin plus rifampicin (all isolates
susceptible), only one (4%) death was reported.
However, the mortality rate was 38% (three of
eight patients) for patients in whom rifampicin
resistance emerged during therapy with the com-
bination. Furthermore, for patients treated with
vancomycin alone, either because the isolate
was rifampicin-resistant or because the drug
was contraindicated, the mortality rate was 78%
(seven of nine patients). In this group of patients
with life-threatening infections caused by EM-
RSA-15, good clinical outcome appeared to be
closely linked to rifampicin susceptibility.
Vancomycin-resistant S. aureus strains have
been isolated from patients in the USA, France,
Korea, South Africa, Brazil, Japan and the UK
[51]. Resistance to vancomycin, which is accom-
plished via cell wall thickening, is acquired
following mutation of S. aureus. Importantly, a
thickened S. aureus cell wall is, thus far, the
common feature of all vancomycin-resistant
S. aureus isolates worldwide [51]. The emergence
of heteroresistant MRSA, i.e., S. aureus with
intermediate glycopeptide susceptibility (MICs
of 4–8 mg ⁄L), may imply that full glycopeptide
resistance is inevitable. This fact suggests that the
Table 2. Inﬂuence of antibiotic concentration on antibac-
terial effect
Marked effect Moderate to no effect
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usefulness of vancomycin may be severely dimin-
ished in the future, underscoring the need for new
therapeutic options.
While vancomycin is the only glycopeptide
available in the USA, teicoplanin is used com-
monly for the management of serious MRSA
infections in Europe, Latin America and Asia, in
both the hospital [52] and the ambulatory setting
[53]. Unlike vancomycin, teicoplanin offers the
advantage of once-daily administration because
of its long half-life. In addition, it can be injected
intramuscularly, which lowers the risk of nephro-
toxicity compared to vancomycin [54]. However,
the emergence of clinically signiﬁcant glyco-
peptide resistance among enterococci [55] and,
more recently, glycopeptide insensitivity in sta-
phylococci [56] have highlighted the need for new
agents to combat these serious infections.
The synthetic streptogramin combination qui-
nupristin–dalfopristin was approved in 1999 for
the treatment of infections with VRE and compli-
cated skin infections. However, resistance to this
combination is already a concern [57]. In clinical
trials of quinupristin–dalfopristin, the occurrence
of resistance in Enterococcus faecium during ther-
apy was observed in ﬁve patients in a multicentre
prospective study evaluating the safety and efﬁc-
acy of quinupristin–dalfopristin in 396 patients
with vancomycin-resistant E. faecium infection
[58]. Four of these cases resulted in clinical failure
and persistence of the resistant bacteria causing
the infection. Other streptogramin-resistant E.
faecium isolates have been recovered in Europe
and the USA, raising concerns about the potential
for emergence and spread of quinupristin–dal-
fopristin–resistant E. faecium [59].
Linezolid is the ﬁrst member of a novel class of
antibacterial agents known as oxazolidinones [60].
Linezolid has in-vitro activity against Enterococcus
faecalis (including vancomycin-resistant strains),
as well as E. faecium (vancomycin-susceptible
strains), Staphylococcus epidermidis (including
methicillin-resistant strains), Staphylococcus hae-
molyticus, Streptococcus pneumoniae (penicillin-
resistant strains), viridans group streptococci,
and vancomycin-resistant S. aureus [60]. Registra-
tion trials with linezolid resulted in its approval
for the treatment of nosocomial pneumonia
caused by S. aureus (methicillin-susceptible and
-resistant strains) or Strep. pneumoniae (penicillin-
susceptible strains only), and complicated skin
and skin structure infections caused by S. aureus
(methicillin-susceptible and -resistant strains),
Streptococcus pyogenes, or Streptococcus agalactiae
(penicillin-susceptible strains only) [61]. Unfortu-
nately, despite the fact that linezolid has received
approval only relatively recently, staphylococcal
resistance to the drug is already developing [62].
This observation has made the need for new
antimicrobial agents even more evident.
Several new antibacterial agents are currently in
phase III of development. The carbapenem doripe-
nem has entered phase III clinical studies in Japan
for the treatment of pneumonia and respiratory
tract infections [63]. Two glycopeptides, oritavan-
cin and dalbavancin, have entered phase III clinical
trials for the treatment of Gram-positive nosoco-
mial infections [63]. Iseganan, a naturally occurring
cationic antimicrobial peptide, is being developed
as an aerosol for the treatment of respiratory
infections in cystic ﬁbrosis patients, and as an oral
solution for the prevention of ventilator-associated
pneumonia in intensive care unit patients [63]. In
addition, two quinolones have reached phase III
trials, i.e., sitaﬂoxacin, which is being studied in
Japan, and garenoxacin, which has completed
phase III trials in the USA and Europe. Phase II
studies in theUSAandEurope showed sitaﬂoxacin
to produce mild ultraviolet phototoxicity in Cau-
casian volunteers, but this toxicity was not appar-
ent in Oriental subjects. An application for
approval of garenoxacin in the USA is expected to
be ﬁled by late 2005 [63].
Of the new agents currently in development,
tigecycline is perhaps the most promising. Tige-
cycline is the ﬁrst of a new synthetic class of
antibiotics, the glycylcyclines [64]. It offers an
extended broad spectrum of activity, including
activity against most methicillin-susceptible and
resistant Gram-positive organisms, as well as
activity against key Gram-negative pathogens
[65]. P. aeruginosa and the Proteaceae are not
well-covered, primarily because of non-speciﬁc
efﬂux mechanisms. Tigecycline does not display
cross-resistance with other classes of antimicro-
bial agents [65]. Moreover, the glycylcyclines have
been speciﬁcally engineered to overcome the
bacterial mechanisms of resistance that rendered
the tetracycline class of agents increasingly less
effective. Indeed, the most notable outcome of a
recent study by Biedenbach et al. [65] was the
absence of observed cross-resistance between
tigecycline and tetracycline, indicating that this
new glycylcycline has signiﬁcant potential
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therapeutic value for infections caused by organ-
isms resistant to tetracycline and tetracycline
derivatives. The same study also demonstrated
an absence of co-resistance for tigecycline with
other common phenotypes, such as oxacillin-
resistant staphylococci, VRE, penicillin-resistant
pneumococci, and enteric bacilli producing
ESBLs. Clinical data for tigecycline are awaited
anxiously, although the ﬁrst two phase II studies
were presented at the Interscience Conference
on Antimicrobial Agents and Chemotherapy in
Chicago, IL, USA during 2003 (abstracts L-738
and L-739). The ﬁrst study examined the safety
and efﬁcacy of tigecycline in the treatment of
complicated skin and skin structure infections in
hospitalised patients, while the second looked at
the efﬁcacy of tigecycline in the treatment of
complicated intra-abdominal infections in hospi-
talised patients. Both studies showed that tigecy-
cline produced an adequate clinical response,
with nausea and vomiting being the adverse
events reported most commonly.
CONCLUSIONS
Hospitalised patients are at greater risk for infec-
tions because of the common use of central
intravenous catheters, indwelling Foley catheters,
ventilators and endotracheal tubes. Numerous
data now indicate that nosocomial infections
caused by resistant organisms, such as MRSA,
VRE and ESBL-producing microorganisms, are
associated with antibiotic treatment failure, as
well as increased morbidity, mortality and health-
care costs. This trend has prompted calls for better
prevention strategies and more judicious use of
current antibiotics. In addition, it has stimulated
the development of new antibiotics, such as
tigecycline with its broad spectrum of activity,
in the hope that such novel therapeutic options
can meet the formidable challenge posed by these
serious hospital-acquired infections.
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